The world has suddenly been alerted to the threat of pandemic influenza with the recent deaths in Asia of patients and their close contacts from which the avian influenza H5N1 virus has been isolated. Experts believe that it is only a matter of time before this virus mutates and acquires the ability to rapidly spread within the human population. The currently available vaccines have virtually no capacity to prevent infection by a new pandemic virus. Once the virus strikes appropriate vaccines ca ....The world has suddenly been alerted to the threat of pandemic influenza with the recent deaths in Asia of patients and their close contacts from which the avian influenza H5N1 virus has been isolated. Experts believe that it is only a matter of time before this virus mutates and acquires the ability to rapidly spread within the human population. The currently available vaccines have virtually no capacity to prevent infection by a new pandemic virus. Once the virus strikes appropriate vaccines can be made against it but this procedure takes at least 6 months, the time predicted for the virus to have already spread throughout the globe. We are proposing that a vaccine designed to induce killer T cells (called CTLs) that target the conserved regions shared by all influenza viruses, could be used as a preventative measure without prior knowledge of the exact type of virus that will emerge. This sort of vaccine will not prevent against infection but will greatly lessen the severity of the disease. We have already designed a vaccine that that will induce high levels of CTLs that can greatly speed up the clearance of viruses of the type that are currently in the human population, when tested in animal models. However, we predict that a new pandemic virus will be much more vigorous in its growth and so our vaccines will have to be improved to cope with this. This project looks at ways of increasing the number and effectiveness of the CTLs that are induced by our vaccines. This will require an understanding of how we can modulate the function of other specialised cells, dendritic cells and helper T cells, that play a role in starting and maintaining the CTL response, as well as modulating the CTLs themselves.Read moreRead less
Heterosubtypic T Cell-inducing Vaccines For Influenza In Humans
Funder
National Health and Medical Research Council
Funding Amount
$352,307.00
Summary
Bird flu virus poses a large risk to the world if it mutates to become easily spread between people. If this occurs vaccines will be made to the mutated strain but there will be a time lag before these are available. We have been working on a novel vaccine that induces protective T cell immunity to parts of the virus that are common to all influenza strains and will be effective against any new virus. Our information from animal models will be used to create a human vaccine of this type .
Centre Of Research Excellence In Infectious Diseases Modelling To Inform Public Health Policy
Funder
National Health and Medical Research Council
Funding Amount
$2,600,064.00
Summary
Infectious diseases pose a global challenge, with substantial human and economic costs. Mathematical models provide valuable frameworks to assess likely benefits of interventions to control infection spread and burden. Leveraging existing NHMRC support, we will expand modeling capability to inform infectious disease control policy in Australia and our region. Focus areas include vaccine preventable disease, respiratory viruses and emerging pathogens, supported by innovative methods development.
Spatiotemporal Risk Assessment Of Emerging Infectious Disease Threats To Australia
Funder
National Health and Medical Research Council
Funding Amount
$641,204.00
Summary
Emerging infectious diseases (EIDs) such as dengue and influenza pose a constant and growing threat to Australians. We live in an increasingly connected world in which EIDs cross borders and oceans, carried by infected people or vectors. This research will build an evidence base for allocation of resources to surveillance and preventive health programmes aimed at mitigating the threat of EIDs, through identifying high-risk sources, routes of introduction, incursion locations and communities.
Platform FoR European Preparedness Against (Re-)emerging Epidemics- Australia
Funder
National Health and Medical Research Council
Funding Amount
$386,463.00
Summary
Infectious diseases rank high among the threats to human wellbeing and prosperity- globalisation, migration, tourism, intensive farming and changing climate enhance the likelihood of emergence of outbreaks of infectious disease. The optimal response to an emerging infectious disease requires the rapid acquisition of new knowledge. This project ensures that Australia can contribute to globally coordinated research that will meet the research challenge associated with any new pandemic infection.
Boosting Effectiveness Of New Vaccines For Dengue ,HFMD And Influenza By Targeting Vaccine Antigens To Clec9A On Dendritic Cells.
Funder
National Health and Medical Research Council
Funding Amount
$396,332.00
Summary
Australian and Singapore laboratories will collaborate to develop improved vaccines against virus diseases, particularly Dengue, Hand Foot and Mouth Disease and Influenza. A novel technology will be used, the targeting of vaccines to a receptor on the surface of the dendritic cells that control immune responses. This will be used to boost responses to a series of vaccine candidates that are otherwise insufficiently immunogenic.
Adapting Pandemic Influenza Interventions And Management To The Newly-emerged Virus
Funder
National Health and Medical Research Council
Funding Amount
$245,098.00
Summary
The Australian Health Management Plan for Pandemic Influenza is based on data from past and current influenza. A newly-emerged influenza strain is likely to differ in some respects. This project will develop practical ways to adapt the management plan to the emerged virus from early pandemic data. It will determine the data needed to do this efficiently, to ensure that Australia receives the greatest benefit from its antiviral drugs, vaccines and other public health interventions introduced.
Macfarlane Adaptive Changes In HIV-1 Subtype C Envelope Glycoproteins Contributing To Pathogenicity.
Funder
National Health and Medical Research Council
Funding Amount
$310,787.00
Summary
HIV exists as multiple subtypes. The most commonly studied is type B (B-HIV). B-HIV is common in developed countries, but accounts for only a small fraction of HIV infections worldwide. Type C HIV (C-HIV) in Africa and Asia accounts for the majority of infections worldwide, yet very little is known about how C-HIV causes AIDS. We aim to understand how C-HIV causes AIDS. This is critical for development of drugs and vaccines specifically designed for those who are most urgently need.